ORKA (Oruka Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ORKA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Laura Lee Sandler | Chief Operating Officer | MIXED | — | — |
| 2026-09-01 | Lawrence Otto Klein | Chief Executive Officer | MIXED | — | — |
| 2026-08-25 | Larry Todd Edwards | Chief Commercial Officer | A | — | — |
| 2026-08-17 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-08-14 | Arjun Agarwal | Senior Vice President, Finance | MIXED | — | — |
| 2026-08-14 | Paul T Quinlan | General Counsel | MIXED | — | — |
| 2026-07-15 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-07-13 | Arjun Agarwal | Senior Vice President, Finance | MIXED | — | — |
| 2026-07-01 | Laura Lee Sandler | Chief Operating Officer | MIXED | — | — |
| 2026-07-01 | Peter Evan Harwin | Director | MIXED | — | — |
| 2026-06-22 | Arjun Agarwal | Senior Vice President, Finance | Sell | — | — |
| 2026-06-15 | Lawrence Otto Klein | Chief Executive Officer | Sell | — | — |
| 2026-06-15 | Laura Lee Sandler | Chief Operating Officer | Sell | — | — |
| 2026-06-15 | Arjun Agarwal | Senior Vice President, Finance | MIXED | — | — |
| 2026-06-15 | Paul T Quinlan | General Counsel | Sell | — | — |
| 2026-06-15 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-06-12 | Carl Dambkowski | Director | Sell | — | — |
| 2026-06-03 | KRISTINE M BALL | Director | A | — | — |
| 2026-06-03 | Christopher Nathan Martin | Director | A | — | — |
| 2026-06-03 | Carl Dambkowski | Director | A | — | — |
| 2026-06-03 | Fairmount Healthcare Fund II L.P. | Director | A | — | — |
| 2026-06-03 | Samarth Kulkarni | Director | A | — | — |
| 2026-05-22 | Carl Dambkowski | Director | MIXED | — | — |
| 2026-05-18 | Arjun Agarwal | Senior Vice President, Finance | MIXED | — | — |
| 2026-05-15 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-05-01 | Laura Lee Sandler | Chief Operating Officer | MIXED | — | — |
| 2026-04-15 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-03-17 | Lawrence Otto Klein | Chief Executive Officer | Sell | — | — |
| 2026-03-17 | Paul T Quinlan | General Counsel | Sell | — | — |
| 2026-03-17 | Laura Lee Sandler | Chief Operating Officer | Sell | — | — |
| 2026-03-17 | Arjun Agarwal | Senior Vice President, Finance | Sell | — | — |
| 2026-03-17 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-03-02 | Laura Lee Sandler | Chief Operating Officer | MIXED | — | — |
| 2026-02-17 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-01-23 | Laura Lee Sandler | Chief Operating Officer | A | — | — |
| 2026-01-23 | Carl Dambkowski | Director | J | — | — |
| 2026-01-23 | Joana Goncalves | Chief Medical Officer | A | — | — |
| 2026-01-23 | Arjun Agarwal | SVP, Finance | A | — | — |
| 2026-01-23 | Paul T Quinlan | General Counsel | A | — | — |
| 2026-01-23 | Lawrence Otto Klein | Chief Executive Officer | A | — | — |
| 2026-01-16 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2026-01-02 | Laura Lee Sandler | Chief Operating Officer | MIXED | — | — |
| 2025-12-19 | Joana Goncalves | Chief Medical Officer | MIXED | — | — |
| 2025-12-11 | Christopher Nathan Martin | Director | A | — | — |
| 2025-09-19 | Tomas Kiselak | Director | A | — | — |
| 2025-07-01 | Laura Lee Sandler | Chief Operating Officer | A | — | — |
| 2025-06-03 | Cameron Turtle | Director | A | — | — |
| 2025-06-03 | Carl Dambkowski | Director | A | — | — |
| 2025-06-03 | KRISTINE M BALL | Director | A | — | — |
| 2025-06-03 | Fairmount Healthcare Co-Invest III L.P. | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,044,684 | — |
| — | Director | 2,573,308 | — |
| — | Director | 1,131,954 | — |
| — | Chief Executive Officer | 993,976 | — |
| — | Director | 638,614 | — |
| — | Chief Operating Officer | 241,384 | — |
| — | Chief Commercial Officer | 100,000 | — |
| — | General Counsel | 54,274 | — |
| — | Director | 51,326 | — |
| — | Chief Medical Officer | 39,718 | — |
| — | Senior Vice President, Finance | 21,080 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORKA quote page; the site-wide leaderboard is on the insider transactions hub.